Considering the stability and easily manufactured nature of protein or peptidyl drugs, it may be more reasonable to develop antagonists of TSHR to avoid systemic side effects, while manifesting effectiveness to inhibit thyroid cancer growth. Here, TSHR is linked to thyroid gland carcinoma.